Marshall Urist - 08 May 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
EVP, Research & Investments
Signature
/s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist
Issuer symbol
RPRX
Transactions as of
08 May 2025
Transactions value $
$0
Form type
4
Filing time
09 May 2025, 17:07:47 UTC
Previous filing
12 Aug 2024
Next filing
20 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Urist Marshall EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK /s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist 09 May 2025 0001838139

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Award $0 +36,484 +78% $0 83,151 08 May 2025 Direct F1
holding RPRX Class A Ordinary Shares 19,020 08 May 2025 By IRA
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.